Literature DB >> 21240494

Successful treatment of sepsis-induced disseminated intravascular coagulation in a patient with idiopathic thrombocytopenic purpura using recombinant human soluble thrombomodulin.

Tomohiro Koga1, Daisuke Inoue, Akitomo Okada, Toshiyuki Aramaki, Satoshi Yamasaki, Munetoshi Nakashima, Atsushi Kawakami, Katsumi Eguchi.   

Abstract

Disseminated intravascular coagulation (DIC) may complicate a variety of disorders that contribute to mortality, particularly those related to bleeding. It is therefore very difficult to manage DIC in patients with known bleeding disorders. We treated a 62-year-old woman with idiopathic thrombocytopenic purpura (ITP) complicated with sepsis-induced DIC. She had been diagnosed with ITP 8 months prior to admission. Laboratory tests showed an elevation of d-dimer and endotoxin, while pyelonephritis was shown by abdominal computed tomography. Escherichia coli was detected by blood culture. Based on these findings, the patient was diagnosed with sepsis-induced DIC due to urinary tract infection. Thrombocytopenia was refractory despite the use of antibiotics and platelet transfusion, but it was promptly improved in response to recombinant human soluble thrombomodulin (rTM). We suggest that rTM provides a new therapeutic strategy for DIC patients with high hemorrhagic risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21240494     DOI: 10.1007/s00296-010-1754-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

Review 1.  Disseminated intravascular coagulation.

Authors:  M Levi; H Ten Cate
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

Review 2.  Disseminated intravascular coagulation: old disease, new hope.

Authors:  Cheng Hock Toh; Michael Dennis
Journal:  BMJ       Date:  2003-10-25

3.  Do-all receptor takes on coagulation, inflammation.

Authors:  Charles Esmon
Journal:  Nat Med       Date:  2005-05       Impact factor: 53.440

4.  Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.

Authors:  T Ikezoe; K Togitani; N Komatsu; M Isaka; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

5.  Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin.

Authors:  M Sakai; T Ikezoe; K Bandobashi; K Togitani; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2009-09-21       Impact factor: 5.483

6.  Effects of human soluble thrombomodulin on experimental glomerulonephritis.

Authors:  Hiroshi Ikeguchi; Shoichi Maruyama; Yoshiki Morita; Yutaka Fujita; Tomomi Kato; Yasuhiro Natori; Hiroyasu Akatsu; William Campbell; Noriko Okada; Hidechika Okada; Yukio Yuzawa; Seiichi Matsuo
Journal:  Kidney Int       Date:  2002-02       Impact factor: 10.612

Review 7.  Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment.

Authors:  Rodger L Bick
Journal:  Hematol Oncol Clin North Am       Date:  2003-02       Impact factor: 3.722

8.  Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.

Authors:  H Saito; I Maruyama; S Shimazaki; Y Yamamoto; N Aikawa; R Ohno; A Hirayama; T Matsuda; H Asakura; M Nakashima; N Aoki
Journal:  J Thromb Haemost       Date:  2006-10-13       Impact factor: 5.824

9.  The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.

Authors:  Kazuhiro Abeyama; David M Stern; Yuji Ito; Ko-ichi Kawahara; Yasushi Yoshimoto; Motoyuki Tanaka; Tomonori Uchimura; Nobuo Ida; Yoshiaki Yamazaki; Shingo Yamada; Yasuhiko Yamamoto; Hiroshi Yamamoto; Satoshi Iino; Noboru Taniguchi; Ikuro Maruyama
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

10.  Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia.

Authors:  Masaru Nagato; Kohji Okamoto; Yukio Abe; Aiichiro Higure; Koji Yamaguchi
Journal:  Crit Care Med       Date:  2009-07       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.